Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atezo plus Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting

被引：0

作者：

Takehara, T. ^{[1
]}

Kato, N. ^{[2
]}

Aikata, H. ^{[3
]}

Kuzuya, T. ^{[4
]}

Hiasa, Y. ^{[5
]}

Nakamura, S. ^{[6
]}

Yamamoto, K. ^{[7
]}

Morimoto, N. ^{[8
]}

Sakamori, R. ^{[9
]}

Kawamura, Y. ^{[10
]}

Tsuchiya, K. ^{[11
]}

Ueshima, K. ^{[12
]}

Hiraoka, A. ^{[13
]}

Nakano, M. ^{[14
]}

Kokudo, N. ^{[15
]}

Furuse, J. ^{[16
]}

Moriguchi, M. ^{[17
]}

Yamashita, T. ^{[18
]}

Ikeda, M. ^{[19
]}

Kudo, M. ^{[12
]}

机构：

[1] Osaka Univ, Grad Sch Med, Gastroenterol & Hepatol, Osaka, Japan

[2] Chiba Univ, Sch Med, Gastroenterol, Chiba, Japan

[3] Hiroshima Prefectural Hosp, Gastroenterol, Hiroshima, Japan

[4] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan

[5] Ehime Univ, Grad Sch Med, Gastroenterol & Metabol, Matsuyama, Ehime, Japan

[6] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[7] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan

[8] Jichi Med Univ Hosp, Dept Gastroenterol, Shimotsuke, Tochigi, Japan

[9] Natl Hosp Org Osaka Natl Hosp, Gastroenterol & Hepatol, Osaka, Japan

[10] Toranomon Gen Hosp, Hepatol, Tokyo, Japan

[11] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[12] Kindai Univ, Fac Med, Gastroenterol & Hepatol, Osaka, Japan

[13] Ehime Prefectural Cent Hosp, Gastroenterol, Matsuyama, Ehime, Japan

[14] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Fukuoka, Japan

[15] NCGM Natl Ctr Global Hlth & Med, Surg, Tokyo, Japan

[16] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[17] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan

[18] Kanazawa Univ Hosp, Gastroenterol Dept, Kanazawa, Ishikawa, Japan

[19] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Chiba, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.221

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

200P

引用

页码：S1480 / S1481

页数：2

共 50 条

[21] Efficacy and safety of durvalumab plus tremelimumab for unresectable hepatocellular carcinoma in Thailand: A real-world multicenter observational study.
Korphaisarn, Krittiya
Wirasorn, Kosin
Tanasanvimon, Suebpong
Thanasombunsukh, Kijjakom
Maneenil, Kunlatida
Thanestada, Jirawat
Teeyapun, Nattaya
Chindaprasirt, Jarin
Sathitruangsak, Chirawadee
Siripoon, Teerada
Tiraswasdichai, Phannin
Charonpongsuntorn, Chanchai
Wanchaijiraboon, Passakorn
Laosuangkoon, Wannisa
Sunpaweravong, Patrapim
Akewanlop, Charuwan
TSCO GI Groups
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 539 - 539
[22] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa
Kaoru Tsuchiya
Masayuki Kurosaki
Yutaka Yasui
Shun Kaneko
Yuki Tanaka
Shun Ishido
Kento Inada
Sakura Kirino
Koji Yamashita
Tsubasa Nobusawa
Hiroaki Matsumoto
Tatsuya Kakegawa
Mayu Higuchi
Kenta Takaura
Shohei Tanaka
Chiaki Maeyashiki
Nobuharu Tamaki
Hiroyuki Nakanishi
Jun Itakura
Yuka Takahashi
Yasuhiro Asahina
Ryuichi Okamoto
Namiki Izumi
Investigational New Drugs, 2022, 40 : 392 - 402
[23] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Hayakawa, Yuka
Tsuchiya, Kaoru
Kurosaki, Masayuki
Yasui, Yutaka
Kaneko, Shun
Tanaka, Yuki
Ishido, Shun
Inada, Kento
Kirino, Sakura
Yamashita, Koji
Nobusawa, Tsubasa
Matsumoto, Hiroaki
Kakegawa, Tatsuya
Higuchi, Mayu
Takaura, Kenta
Tanaka, Shohei
Maeyashiki, Chiaki
Tamaki, Nobuharu
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Asahina, Yasuhiro
Okamoto, Ryuichi
Izumi, Namiki
INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 392 - 402
[24] INITIAL EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD CLINICAL PRACTICE
Iwamoto, Hideki
Shimose, Shigeo
Takashi, Niizeki
Noda, Yu
Shirono, Tomotake
Nakano, Masahito
Okamura, Shusuke
Kamachi, Naoki
Suzuki, Hiroyuki
Kuromatsu, Ryoko
Koga, Hironori
Torimura, Takuji
HEPATOLOGY, 2021, 74 : 652A - 652A
[25] Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Iwamoto, Hideki
Shimose, Shigeo
Noda, Yu
Shirono, Tomotake
Niizeki, Takashi
Nakano, Masahito
Okamura, Shusuke
Kamachi, Naoki
Suzuki, Hiroyuki
Sakai, Miwa
Kajiwara, Akira
Itano, Satoshi
Tanaka, Masatoshi
Yamaguchi, Taizo
Kuromatsu, Ryoko
Koga, Hironori
Torimura, Takuji
CANCERS, 2021, 13 (11)
[26] Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study
Charonpongsuntorn, Chanchai
Tanasanvimon, Suebpong
Korphaisarn, Krittiya
Payapwattanawong, Songwit
Siripoon, Teerada
Pakvisal, Nussara
Juengsamarn, Jitlada
Phaibulvatanapong, Ekkamol
Chindaprasirt, Jarin
Prasongsook, Naiyarat
Udomdamrongkul, Kittipong
Ngamphaiboon, Nuttapong
Sirachainan, Ekaphop
JCO GLOBAL ONCOLOGY, 2022, 8 : e2200205
[27] Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
Ando, Yuwa
Kawaoka, Tomokazu
Kosaka, Masanari
Shirane, Yuki
Johira, Yusuke
Miura, Ryoichi
Murakami, Serami
Yano, Shigeki
Amioka, Kei
Naruto, Kensuke
Kosaka, Yumi
Uchikawa, Shinsuke
Kodama, Kenichiro
Fujino, Hatsue
Nakahara, Takashi
Ono, Atsushi
Murakami, Eisuke
Yamauchi, Masami
Okamoto, Wataru
Takahashi, Shoichi
Imamura, Michio
Chayama, Kazuaki
Aikata, Hiroshi
CANCERS, 2021, 13 (16)
[28] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study
Kim, Y. J.
Kurosaki, M.
Numata, K.
Lim, H. Y.
Ikeda, M.
Kudo, M.
Huang, Y-H.
Shao, G.
Kato, N.
Kim, D-Y.
Cho, S-B.
Hsu, C-H.
Lin, S-M.
Jeng, L-B.
Kuo, K-K.
Mao, Y.
Chewaskulyong, B.
Khan, J.
Ozgurdal, K.
Qin, S.
ANNALS OF ONCOLOGY, 2022, 33 : S1459 - S1460
[29] Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Naganuma, Atsushi
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Kouji
Iijima, Hiroko
Hiasa, Yoichi
CANCER MEDICINE, 2022, 11 (20): : 3796 - 3808
[30] EMERGING REAL-WORLD TREATMENT PATTERNS FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (uHCC) PATIENTS FOLLOWING APPROVAL OF ATEZOLIZUMAB PLUS BEVACIZUMAB (A plus B) IN THE UNITED STATES (US)
Singal, Amit G.
Shamas, Natasha
Secrest, Matthew H.
Mahrus, Sami
Tan, Amie
Li, Daneng
HEPATOLOGY, 2022, 76 : S1381 - S1382

← 1 2 3 4 5 →